Cure My Disease

Don't miss your cure!

 Log in / Sign up

New furosemide shot tested as easier alternative to IV

NCT ID NCT07269496

Knowledge-focused Sponsor: SQ Innovation, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new way to give furosemide (a water pill) by injecting it under the skin instead of into a vein. Sixteen healthy volunteers received both versions to see how well the body absorbs the drug. The goal is to find out if the under-the-skin shot works as well as the IV, which could make treatment more convenient.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
furosemide (a water pill)
What this could lead to
If successful, this could lead to a more convenient way to give furosemide under the skin instead of through a vein, potentially allowing easier treatment for fluid retention.
What could go wrong
This is a very early, small study in healthy people, not patients. It only checks how the drug is absorbed, not if it works better or is safer. The new shot may not work as well as the IV form.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

16 people

The number who actually took part.

Started

Feb 2026

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent * Male or female ≥18 years of age * BMI between 18.5 and 32.0 kg/m2 (inclusive) * Females will be non-pregnant and non-lactating * Able to participate in the study in the opinion of the Investigator * Has the ability to understand the requirements of the study and is willing to comply with all study procedures Exclusion Criteria: * Unable to consent to inclusion in study * eGFR \< 60 mL/min/1.73 m2 * Use of diuretics * Systolic blood pressure (SBP) \<90 mmHg * Potassium \< 3.5 or \> 5.3 mmol/L * Sodium \< 133 or \> 146 mmol/L * Comorbidities or health issues which in the opinion of the investigator may interfere with study participation or study assessments. * Major surgery within 30 days prior to Screening. * Administration of an investigational drug or implantation of investigational device, or participation in another interventional trial, within 30 days prior to Screening, or 5 half-lives, whichever is longer. * Pregnancy or breastfeeding * Any contraindications for furosemide administration as per furosemide SmPC * Any surgical or medical conditions, which in the opinion of the investigator may pose an undue risk to the participant, interfere with participation in the study or which may affect the integrity of the data * Any clinically significant findings in Screening laboratory results which in the opinion of the investigator may pose an undue risk to the participant, interfere with participation in the study or which may affect the integrity of the data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy

Contacts and locations

Locations

  • BDD Pharma

    Glasgow, Scotland, G4 0SF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.